COPD News Today Home | COPD News Today
FDA approves first RSV vaccine for at-risk adults younger than 50. The U.S. Food and Drug Administration (FDA) has approved Abrysvo, a vaccine that protects against lung infections caused by the respiratory syncytial virus — commonly known as RSV — for adults as young as 18 with chronic obstructive pulmonary disease (COPD) or other conditions that increase the risk of…
1st approved Symbicort generic, Breyna, now available in US
Aug 7, 2023 · The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available to eligible patients.. Like Symbicort, Breyna is approved as a maintenance therapy to lower airflow obstruction and prevent exacerbations in people with COPD, and for asthma patients, ages 6 and older.
News Archives - COPD News Today
FDA approves first RSV vaccine for at-risk adults younger than 50. The U.S. Food and Drug Administration (FDA) has approved Abrysvo, a vaccine that protects against lung infections caused by the respiratory syncytial virus — commonly known as RSV — for adults as young as 18 with chronic obstructive pulmonary disease (COPD) or other conditions that increase the risk of…
Dupixent approved in US for adults with poorly controlled COPD
Sep 30, 2024 · In the U.S., the expansion of Dupixent’s label to include COPD brings the number of approved indications up to six, adding to its use as a treatment for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis — all driven in part by type 2 inflammation. “Dupixent has already shown it can revolutionize the treatment paradigm ...
FDA approves first RSV vaccine for at-risk adults younger than 50
Oct 28, 2024 · The U.S. Food and Drug Administration (FDA) has approved Abrysvo, a vaccine that protects against lung infections caused by the respiratory syncytial virus — commonly known as RSV — for adults as young as 18 with chronic obstructive pulmonary disease (COPD) or other conditions that increase the risk of such infections.
FDA delays decision on Dupixent for COPD until September
Jun 3, 2024 · Clinical trials of Dupixent for COPD. The applications are supported by two Phase 3 trials, BOREAS (NCT03930732) and NOTUS (NCT04456673), each involving more than 900 current or former smokers with COPD.All had signs of type 2 inflammation and uncontrolled disease despite using standard inhaled therapies, which …
Dupixent shown to reduce COPD exacerbations in 2nd clinical trial
Dec 4, 2023 · Dupixent use also resulted in better lung function for these COPD patients, per an interim analysis of the NOTUS study (NCT04456673), which is expected to conclude in 2024.. The positive findings were robust enough for them to be considered the result of a main analysis, according to the therapy’s developers Sanofi and Regeneron Pharmaceuticals.The companies expect to present detailed trial ...
Trelegy Ellipta Reduces COPD Exacerbations and Improves Lung …
Apr 24, 2018 · The Phase 3 IMPACT study compared Trelegy to other common COPD medications in 10,355 patients in 37 countries, according to GlaxoSmithKline (GSK) and Innoviva.. Findings from the study, titled “Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD,” were recently published in the New England Journal of Medicine. Trelegy Ellipta was approved as a maintenance treatment ...
Low-dose Morphine Improves Health in COPD Patients With …
Sep 3, 2020 · So, researchers based at the Maastricht University in the Netherlands designed the Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) Phase 4 study (NCT02429050).It investigated whether regular, low-dose, oral sustained-release morphine improved health in COPD patients with moderate-to-very-severe chronic breathlessness.
COPD Trial Shows Breztri Aerosphere Significantly Reduces...
Jun 30, 2020 · The findings were presented by the company at the American Thoracic Society virtual Scientific Symposium and published in The New England Journal of Medicine, in an article titled “ Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.”. Breztri Aerosphere, known as PT010 outside of China, is a triple combination therapy made up of the inhalable corticosteroid ...